189 related articles for article (PubMed ID: 18050376)
1. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.
Haggerty HG; Abbott MA; Reilly TP; DeVona DA; Gleason CR; Tay L; Dodge R; Aranda R
J Rheumatol; 2007 Dec; 34(12):2365-73. PubMed ID: 18050376
[TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
3. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
4. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
5. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis.
Weisman MH; Durez P; Hallegua D; Aranda R; Becker JC; Nuamah I; Vratsanos G; Zhou Y; Moreland LW
J Rheumatol; 2006 Nov; 33(11):2162-6. PubMed ID: 17014006
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
7. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
8. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
9. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.
Keystone EC; Kremer JM; Russell A; Box J; Abud-Mendoza C; Elizondo MG; Luo A; Aranda R; Delaet I; Swanink R; Gujrathi S; Luggen M
Ann Rheum Dis; 2012 Jun; 71(6):857-61. PubMed ID: 22302417
[TBL] [Abstract][Full Text] [Related]
10. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
Shergy WJ
Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
[TBL] [Abstract][Full Text] [Related]
11. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D
Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
13. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
[TBL] [Abstract][Full Text] [Related]
14. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.
Moreland LW; Alten R; Van den Bosch F; Appelboom T; Leon M; Emery P; Cohen S; Luggen M; Shergy W; Nuamah I; Becker JC
Arthritis Rheum; 2002 Jun; 46(6):1470-9. PubMed ID: 12115176
[TBL] [Abstract][Full Text] [Related]
15. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization.
Koenders MI; Marijnissen RJ; Joosten LA; Abdollahi-Roodsaz S; Di Padova FE; van de Loo FA; Dulos J; van den Berg WB; Boots AM
Arthritis Rheum; 2012 Jun; 64(6):1762-70. PubMed ID: 22213107
[TBL] [Abstract][Full Text] [Related]
16. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
17. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.
Nash P; Nayiager S; Genovese MC; Kivitz AJ; Oelke K; Ludivico C; Palmer W; Rodriguez C; Delaet I; Elegbe A; Corbo M
Arthritis Care Res (Hoboken); 2013 May; 65(5):718-28. PubMed ID: 23097311
[TBL] [Abstract][Full Text] [Related]
19. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
Sibilia J; Westhovens R
Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
[TBL] [Abstract][Full Text] [Related]
20. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
